Research and Policy CSR News

Chairman and CEO Alex Gorsky Profiled by the Financial Times About Johnson & Johnson's Work on a Potential Covid-19 Vaccine

The article explores what guided the decision, which is just the latest example of our Chairman and CEO's people-first approach to leadership at our healthcare company.
Article

Johnson & Johnson scientists are fast at work on a potential vaccine for Covid-19 that our company plans to provide on a not-for-profit basis.

“I’m a Scientist Working on a Potential Covid-19 Vaccine”: Meet a Researcher Who's Studying a Promising Candidate

Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
Blog

Weeks before many people had even heard of the novel coronavirus, Roland Zahn, Ph.D., was already studying the disease—specifically, how it could be stopped.​

A COVID-19 Roadmap for Oral Solid Dosage Manufacturers

OSD products show great promise as treatments for the symptoms of COVID-19.
Blog

The global pandemic and economic shutdown facing us today is unlike anything most of us have seen in our lifetime. Around the world, the threat of COVID-19 has forced everyday life to come to a standstill. 

ATMP Facilities: The Cost of Manufacturing a Magic Bullet

Essential strategies to position your ATMP facility for success.
Blog

It’s a thrilling time to be part of an advanced therapy medicinal product (ATMP) project. You’re working on a new frontier of scientific discovery, using some of the fastest-evolving and most complex techniques available to potentially cure our most malignant diseases. For patients and drug developers alike, ATMP manufacturing could be a dream come true.

The Road to a Vaccine, Ep. 1: How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Providing Critical Resources to HCPs in Time of Crisis

Blog

Published on March 27, 2020
by Sandra Humbles, Vice President, Global Education Solutions, Johnson & Johnson Medical Devices

Today, the heroic healthcare professionals (HCPs) on the front lines of care in communities around the world need our support more than ever before.

"I Have Never Seen a Moment So Rich in Collaboration, Ingenuity and Acts of Bravery": Johnson & Johnson Announces It Has Identified a Lead Covid-19 Vaccine Candidate

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.
Blog

By Alex Gorsky, Chairman & CEO, 

The Covid-19 pandemic is one of the greatest challenges to our society in living memory.

Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.

Hilton and American Express to Donate Up to 1 Million Rooms to Frontline Medical Professionals During COVID-19 Crisis

Press Release

Hilton (NYSE:HLT) and American Express (NYSE:AXP) today announced that the companies, in partnership with Hilton’s ownership community, will donate up to 1 million hotel room nights across the United States to frontline medical professionals leading the fight against COVID-19.

Beginning next week, Hilton and American Express will make rooms available without charge to doctors, nurses, EMTs, paramedics and other frontline medical staff who need a place to sleep, recharge or isolate from their families through the end of May.

COVID-19 Brings Policy Responses, Risks to Emerging Markets, and Hoarding

Growing policy responses reflect greater estimates of the costs of COVID-19.
Summary: 

By Carl R. Tannenbaum, Ryan James Boyle, Vaibhav Tandon

SUMMARY

  • Policy Expands to Counter Economic Contraction

  • Emerging Markets Are Under Rising Pressure

  • The Rationale Behind Hoarding
Article

By Carl R. Tannenbaum, Ryan James Boyle, Vaibhav Tandon

SUMMARY

  • Policy Expands to Counter Economic Contraction

  • Emerging Markets Are Under Rising Pressure

  • The Rationale Behind Hoarding

Keys to Accelerating Your COVID-19 Drug Campaign

As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.
Press Release

March, 2020 - /3BL Media/ - Industry leaders are jousting with questions of how to quickly evaluate new and repurposed drugs while simultaneously readying their operations for rapid transformation. Novel partnerships between private R&D teams and public health agencies are emerging to address the “discovery” half of that equation, which leaves company leaders to grapple with the other half: how can they prepare their operations for commercial-scale manufacturing of a therapy that hasn’t yet been identified or approved? 

Pages

Subscribe to Research and Policy